甲氨蝶呤联合替莫唑胺对原发性中枢神经系统淋巴瘤患者的疗效分析

摘要

目的:探讨甲氨蝶呤联合替莫唑胺对原发性中枢神经系统淋巴瘤的临床疗效.方法:选取原发性中枢神经系统淋巴瘤患者48例,随机分为研究组24例和对照组24例.研究组采用大剂量甲氨蝶呤联合替莫唑胺进行化疗,对照组给予大剂量甲氨蝶呤联合全脑放疗.治疗后,比较2组的治疗有效率及不良反应.结果:治疗后,对照组和研究组的有效率分别为54.2％、83.3％,研究组的有效率高于对照组(x2=4.752,P＜0.05).研究组的骨髓抑制程度低于对照组(P＜0.05).对照组和研究组的1年生存率分别为(73.6±4.8)％、(82.4士6.7)％,研究组的1年生存率高于对照组(x2=21.531,P=0.041).结论:在治疗原发性中枢神经系统淋巴瘤时,采用大剂量甲氨蝶呤联合替莫唑胺化疗方案的临床疗效较好,安全性较高.%Objective:To investigate the therapeutic efficacy of Methotrexate combined with Temozolomide for treating primary central nervous system lymphoma.Methods:Forty-eight patients with primary central nervous system lymphoma were randomized into study group and control group,with 24 cases in each group.The study group was treated by high dose of Methotrexate and Temozolomide.The control group was treated by high dose of Methotrexate combined with whole brain radiotherapy.The efficacy and adverse reaction were compared between the two groups.Results:After the treatment,the efficiency rate in the control group and study group were 54.2％,83.3％ respectively.And the efficiency rate of study group was higher than that of control group (P＜0.05).The 1-year survival rates of the control group and study group were 73.6％,82.4％ respectively.The survival rate in study group was significantly better than that in control group(P＜0.05).Conclusion:Intravenous injection of high-dose Methotrexate combined with Temozolomide is a good remedy and safe for primary central nervous system lymphoma.